PD-1 Monoclonal Antibody With Recombinant Human Adenovirus Type 5 Injection for the Treatment of Advanced Malignant Melanoma Patients Who Has Failed Immunotherapy: an Exploratory Single-arm Study.

Safety of PD1 monoclonal antibody combined with recombinant human adenovirus type 5 injection in patients with advanced malignant melanoma." Keywords: Adenovirus; Antibodies; Blood Proteins; Cancer; Clinical Research; Clinical Trials and Studies; Contraception; Contraceptives; DNA Viruses; DNA Viruses - Mastadenovirus; Drugs and Therapies; Gender Health; Gender and Health; Genetics; Health and Medicine; Human Adenoviruses; Immunoglobulins; Immunology; Immunoproteins; Immunotherapy; Mastadenovirus; Melanoma; Monoclonal Antibodies; Monoclonal Antibody; Oncology; Proteins; Reproductive Medicine; Reproductive Techniques; Vertebrate Viruses; Viral; Virology; Women's Health EN Adenovirus Antibodies Blood Proteins Cancer Clinical Research Clinical Trials and Studies Contraception Contraceptives DNA Viruses DNA Viruses - Mastadenovirus Drugs and Therapies Gender Health Gender and Health Genetics Health and Medicine Human Adenoviruses Immunoglobulins Immunology Immunoproteins Immunotherapy Mastadenovirus Melanoma Monoclonal Antibodies Monoclonal Antibody Oncology Proteins Reproductive Medicine Reproductive Techniques Vertebrate Viruses Viral Virology Women's Health 690 690 1 07/17/23 20230717 NES 230717 2023 JUL 18 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Staff editors report on the newly launched clinical trial, NCT05928962, which has the following summary description: "The goal of this clinical trial is provide new treatment for patients with advanced melanoma who have failed previous immunotherapy. [Extracted from the article]